AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit)
May 05, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
Received ~$2.52 million in aggregate CIR payments in 2020CIR to be used to fund on-going MS1819 Phase 2 clinical studies in Europe NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
December 19, 2018 08:00 ET
|
AzurRx BioPharma, Inc.
First site initiated at the Cystic Fibrosis InstituteInitial top line data expected in 2019 NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the...